A BEVY of good news for GUMM yet the stock continues to SINK!!
To: Doug R who started this subject
From: Bo Didley Thursday, Sep 14, 2000 7:54 PM ET
Reply # of 37370
* * GUMM * * Chart ready for breakout
stockcharts.com[L,A]DAOL...
Notice the accumulation, money flow, upward trend breaking out of an ascending triangle.
Info: GUMM owns Zicam. Remedy for the common cold. Played here last January and ran it to $36. Guess what, its back in play, buy now and you'll be early, imo.
zicam.com -- What's coming up is research clinicals in a journal that shows Zicam effective reducing
a 14 day common cold to last only 3 days. That is revolutionary!
We know
1. Dr. Hirt conducted research using Zicam
at onset. One study yielded 78% another one 72% effective, respectfully. The news release said he would submit these to a journal. He has two studies he could submit separately, or combine them into one. I would expect a journal to publish these to correspond with the seasonality of the common cold. When this is released, expect a strong move in the price.
Human interest momentum from possible talk on TV News and
other media. (They hired Kovel Fuller to do the PR kovelfuller.com
2. We know independant research on Zicam
has been on going for the Preventative claims.
In a news released dated July 1999, GUMM announced they would be seeking data for Zicam PREVENTING the common cold.
Some believe Dr. Turner, the most respected, world known rhinovirus virologist has been conducting the studies. He did the research for VPHM, which research moved it from $11's to $111. He's had plenty of time to complete the research for ZICAM. Same reasoning, I would expect news of Preventative status to occur sometime during the seasonality of the
common cold. American populous is very big
on prevention of illness. So is the medical
community. If the studies show significant
statistics and Dr. Turner is the head Investigator, this will be huge huge news. Zicam is already in over 50,000 stores and Preventative Claims would promote it well in
hospitals and clinics, a life saving medicine among the immunosuppressed patients. But it needs credible research first
showing significant statistics by a well known researcher.
The Chart and the above two reasons is why I am back in GUMM to correspond with the seasonality of news and journals.
This is a short term, seasonal investment.
Other information at gumminvestors.com
If you like this as an investment, let your friends know
about it.
bo |
